Rate My Professor Anoop Enjeti

Dr. Anoop Enjeti is a Conjoint Associate Professor in the School of Medicine and Public Health at the University of Newcastle. He is a clinician researcher and clinical haematologist with dual clinical fellowships in Physician and Pathology. His academic qualifications include an MBBS and MD from Pondicherry University, a PhD from the University of Newcastle, a Master of Clinical Epidemiology in Molecular and Genetic Epidemiology from the University of Newcastle, a Graduate Certificate in Bioethics from Monash University, a Master Certificate in Healthcare Leadership from Cornell University USA, a Postgraduate Certificate in Nanotechnology from Oxford University UK, and a Certificate of Competence in Lymphoma from Ulm University Germany. He holds fellowships from the Royal College of Physicians UK, Royal College of Pathologists of Australia, American College of Physicians, and American Society of Clinical Pathology.

Enjeti has served as Senior Staff Specialist Haematologist at Calvary Mater Newcastle Hospital since 2011, Director of Haematology at NSW Health Pathology since 2020, and Translational Research Fellow from 2017 to 2020. He is the clinical lead for the acute myeloid leukemia and myelodysplasia program at Calvary Mater Hospital, Molecular Haematology Lead establishing the state-wide molecular haematology sequencing platform, and MDS trials lead for the Australasian Leukaemia and Lymphoma Group. His research interests encompass acute leukemia and myelodysplasia, genomics for haematological malignancies, microvesicles, and thrombosis and haemostasis. He has authored over 120 publications, including "Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation" (2023), "Proteogenomics Coupled with Ex Vivo Profiling for Therapeutic Targeting in AML" (2023), "Development of the Treatment Preference in Myelodysplasia Questionnaire" (2023), and contributions to phase trials on venetoclax, azacitidine, and FLT3 inhibitors. Awards include a visiting fellowship in Molecular Oncologic Pathology funded by the Terry Fox Foundation (2016) and a Translational Research Fellowship (2017-2020). He has secured over $3 million in funding, including an NHMRC Ideas grant, supervises PhD students and fellows, and holds roles as President of the Thrombosis and Haemostasis Society of Australia and New Zealand and chief examiner for Haematology at the Royal College of Pathologists of Australia.